Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 103 articles:
HTML format
Text format



Single Articles


    October 2019
  1. CHIHOTA BV, Wandeler G, Chilengi R, Mulenga L, et al
    High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
    J Infect Dis. 2019 Oct 15. pii: 5581876. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. SU TH, Peng CY, Tseng TC, Yang HC, et al
    Serum Mac-2-binding protein glycosylation isomer at virological remission predicts hepatocellular carcinoma and death in chronic hepatitis B related cirrhosis.
    J Infect Dis. 2019 Oct 1. pii: 5580041. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2019
  3. ZOU B, Yeo YH, Le MH, Henry L, et al
    Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016.
    J Infect Dis. 2019 Sep 27. pii: 5575100. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. YANG HI, Yeh ML, Wong GL, Peng CY, et al
    REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy.
    J Infect Dis. 2019 Sep 24. pii: 5573337. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. YE J, Wu Y, Li M, Gong X, et al
    Keratin 8 mutations were associated with susceptibility to chronic hepatitis B and related progression.
    J Infect Dis. 2019 Sep 13. pii: 5568471. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2019
  6. TRESSLER SR, Kushner T, Bhandari R
    Factors Associated with Hepatitis B Exposure among People who Report Using Methamphetamine: NHANES 2009-2016.
    J Infect Dis. 2019 Aug 30. pii: 5556601. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. EMMANUEL B, El-Kamary SS, Magder LS, Stafford KA, et al
    Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.
    J Infect Dis. 2019 Aug 26. pii: 5554606. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. CHOI YH, Perez-Cuevas MB, Kodani M, Zhang X, et al
    Feasibility of Hepatitis B Vaccination by Microneedle Patch: Cellular and Humoral Immunity Studies in Rhesus Macaques.
    J Infect Dis. 2019 Aug 13. pii: 5549399. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. WANG K, Lin W, Kuang Z, Fan R, et al
    Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients.
    J Infect Dis. 2019 Aug 2. pii: 5542793. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2019
  10. MARTIN NK, Jansen K, An der Heiden M, Boesecke C, et al
    Can HCV be eliminated among HIV-positive men who have sex with men in Berlin? A modeling analysis.
    J Infect Dis. 2019 Jul 12. pii: 5532024. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2019
  11. OLBRICH A, Wardemann H, Bohm S, Rother K, et al
    Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C.
    J Infect Dis. 2019 Jun 4. pii: 5511345. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. HAN JW, Sung PS, Kim KH, Hong SH, et al
    Dynamic Changes in Ex Vivo T-Cell Function after Viral Clearance in Chronic HCV Infection.
    J Infect Dis. 2019 Jun 1. pii: 5510067. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  13. YAN Y, Wang X, Lou P, Hu Z, et al
    A nanoparticle-based HCV vaccine with enhanced potency.
    J Infect Dis. 2019 May 10. pii: 5487910. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. LAIDLAW SM, Dustin LB
    An HCV vaccine on the fly.
    J Infect Dis. 2019 May 10. pii: 5487908. doi: 10.1093.
    PubMed     Text format    


  15. SAYED IM
    Hepatic immune response against Hepatitis E virus genotype 1 infection among animal models.
    J Infect Dis. 2019 May 7. pii: 5486414. doi: 10.1093.
    PubMed     Text format    


  16. LIU F, Seto WK, Wong DK, Huang FY, et al
    Plasma fibronectin levels identified via quantitative proteomics profiling predicts hepatitis B surface antigen seroclearance in chronic hepatitis B.
    J Infect Dis. 2019 May 6. pii: 5485908. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  17. OESER C, Vaughan A, Said B, Ijaz S, et al
    Epidemiology of Hepatitis E in England and Wales: A 10-Year Retrospective Surveillance Study, 2008-2017.
    J Infect Dis. 2019 Apr 24. pii: 5479512. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. SAYED IM, Verhoye L, Montpellier C, Abravanel F, et al
    Study of hepatitis E virus ORF2 antigen kinetics in human-liver chimeric mice and its impact on HEV diagnosis.
    J Infect Dis. 2019 Apr 18. pii: 5475180. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed     Text format    


  20. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  21. BOCKMANN JH, Stadler D, Xia Y, Ko C, et al
    Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes.
    J Infect Dis. 2019 Mar 29. pii: 5421826. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. ABARA WE, Trujillo L, Broz D, Finlayson T, et al
    Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015.
    J Infect Dis. 2019 Mar 27. pii: 5420467. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. ZHANG Z, Liang Z, Zeng J, Zhang J, et al
    Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with recombinant hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase IV, open-label, single-center, randomized, non-inferiority tr
    J Infect Dis. 2019 Mar 19. pii: 5395971. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  24. SALAZAR-VIZCAYA L, Kouyos RD, Metzner KJ, Caraballo Cortes K, et al
    Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era.
    J Infect Dis. 2019 Feb 13. pii: 5318573. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. LEUNG J, Peacock A, Colledge S, Grebely J, et al
    A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs - do gender differences vary by country-level indicators?
    J Infect Dis. 2019 Feb 6. pii: 5307802. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  26. LIU KSH, Seto WK, Lau EHY, Wong DK, et al
    A territory-wide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong.
    J Infect Dis. 2019 Jan 18. pii: 5298202. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. CHEN CH, Hung CH, Wang JH, Lu SN, et al
    The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy.
    J Infect Dis. 2019 Jan 17. pii: 5299647. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. ANDONOV A, Robbins M, Borlang J, Cao J, et al
    Rat hepatitis E virus linked to severe acute hepatitis in an immunocompetent patient.
    J Infect Dis. 2019 Jan 11. pii: 5288497. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. RAGHWANI J, Wu CH, Ho CKY, De Jong M, et al
    High resolution evolutionary analysis of within-host hepatitis C virus infection.
    J Infect Dis. 2019 Jan 2. pii: 5269822. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  30. NASTASIO S, Jonas MM
    Editorial: The Impact of Universal Infant Hepatitis B Virus Immunization on reducing the Hepatitis B Carrier Rate in Pregnant Women.
    J Infect Dis. 2018 Dec 20. pii: 5253870. doi: 10.1093.
    PubMed     Text format    


  31. SU WJ, Chen SF, Yang CH, Chuang PH, et al
    The Impact of Universal Infant Hepatitis B Immunization on reducing the Hepatitis B Carrier Rate in Pregnant Women.
    J Infect Dis. 2018 Dec 20. pii: 5253892. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  32. PIROZYAN MR, Nguyen N, Cameron B, Luciani F, et al
    Chemokine-regulated recruitment of antigen-specific T cell sub-populations to the liver in acute and chronic hepatitis C infection.
    J Infect Dis. 2018 Nov 29. pii: 5213654. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. PRICE JC, McKinney JE, Crouch PC, Dillon SM, et al
    Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV.
    J Infect Dis. 2018 Nov 20. pii: 5193510. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. YEH ML, Huang CI, Huang CF, Hsieh MH, et al
    Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.
    J Infect Dis. 2018 Nov 19. pii: 5191105. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  35. LAROUCHE A, Milton McSween KA, Calderon V, Fauteux-Daniel S, et al
    Quasispecies Diversity Is a Major Risk Factor for Vertical Hepatitis C Virus Transmission.
    J Infect Dis. 2018 Oct 25. pii: 5144832. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. THAN TT, Jo E, Todt D, Nguyen PH, et al
    High environmental stability of hepatitis B virus and inactivation requirements for chemical biocides.
    J Infect Dis. 2018 Oct 24. pii: 5144374. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. CHOI Y, Zhang X, Skinner B
    Analysis of IgG anti-HEV antibody protective levels during hepatitis E virus reinfection in experimentally infected rhesus macaques.
    J Infect Dis. 2018 Oct 16. pii: 5132976. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. TURPIN J, Yurick D, Khoury G, Pham H, et al
    Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia.
    J Infect Dis. 2018 Oct 11. pii: 5126831. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  39. TANG L, Chen C, Gao X, Zhang W, et al
    Interleukin-21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection.
    J Infect Dis. 2018 Sep 27. pii: 5107682. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. LANDAHL J, Bockmann JH, Scheurich C, Ackermann C, et al
    Detection of a broad range of low level MHC class II-restricted Hepatitis Delta Virus (HDV)-specific T cell responses regardless of the clinical status.
    J Infect Dis. 2018 Sep 23. pii: 5106138. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  41. ANKCORN M, Moreira F, Ijaz S, Symes A, et al
    Absence of persistent Hepatitis E virus infection in antibody-deficient patients is associated with the transfer of antigen neutralising antibodies from immunoglobulin products.
    J Infect Dis. 2018 Aug 18. pii: 5075995. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. THOENS C, Heinold A, Lindemann M, Horn PA, et al
    A single nucleotide polymorphism upstream of the HLA-C locus is associated with an anti-HCV seronegative state in a high-risk exposed cohort.
    J Infect Dis. 2018 Aug 9. pii: 5068404. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. VELAZQUEZ-MOCTEZUMA R, Galli A, Law M, Bukh J, et al
    Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance.
    J Infect Dis. 2018 Aug 9. pii: 5068268. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  44. LOPEZ-CORTES LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis. 2018 Jul 6. pii: 5050122. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. NGUYEN MH, Yang HI, Le A, Henry L, et al
    Reduced Incidence of Hepatocellular Carcinoma with Tenofovir in Chronic Hepatitis B Patients with and without Cirrhosis - a Propensity Score Matched Study.
    J Infect Dis. 2018 Jul 5. pii: 5049301. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  46. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. HELFRITZ FA, Bojkova D, Wanders V, Kuklinski N, et al
    Methylene Blue Treatment of Grafts during Cold Ischemia time Reduces the Risk of HCV Transmission.
    J Infect Dis. 2018 Jun 23. pii: 5043304. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. HONER ZU SIEDERDISSEN C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, et al
    Contrasting Timing of Virological Relapse after Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-negative Patients.
    J Infect Dis. 2018 Jun 9. pii: 5035294. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. LIDOFSKY A, Holmes JA, Feeney ER, Kruger AJ, et al
    Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection.
    J Infect Dis. 2018 Jun 4. pii: 5032604. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  50. MAHALE P, Aka PV, Chen X, Liu P, et al
    Hepatitis D Viremia Among Injection Drug Users in San Francisco.
    J Infect Dis. 2018;217:1902-1906.
    PubMed     Text format     Abstract available


  51. VAN BOMMEL F, van Bommel A, Krauel A, Wat C, et al
    Serum HBV RNA as a Predictor of Peginterferon Alfa-2a (40KD) Response in Patients With HBeAg-Positive Chronic Hepatitis B.
    J Infect Dis. 2018 May 8. pii: 4993824. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. LEE IC, Yang SS, Lee CJ, Su CW, et al
    Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study.
    J Infect Dis. 2018 May 7. pii: 4993347. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  53. MAY S, Mandal S, Keel P, Haywood B, et al
    Hepatitis B virus immunisation and neonatal acquisition of persistent infection in England and Wales.
    J Infect Dis. 2018 Apr 24. pii: 4982944. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. LIN KY, Hsieh SM, Sheng WH, Lo YC, et al
    Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan.
    J Infect Dis. 2018 Apr 16. pii: 4972613. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  55. FRITZ M, Berger B, Schemmerer M, Endres D, et al
    Pathological Cerebrospinal Fluid Findings in Patients with Neuralgic Amyotrophy and Acute Hepatitis E Virus Infection.
    J Infect Dis. 2018 Mar 14. pii: 4935502. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. RAGONNET-CRONIN M, Jackson C, Bradley-Stewart A, Aitken C, et al
    Recent and Rapid Transmission of HIV among People who Inject Drugs in Scotland Revealed through Phylogenetic Analysis.
    J Infect Dis. 2018 Mar 13. pii: 4931169. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. COOPER CL
    Now is the Time to Quickly Eliminate Barriers along the Hepatitis C Cascade of Care.
    J Infect Dis. 2018 Mar 9. pii: 4925219. doi: 10.1093.
    PubMed     Text format    


  58. LAMOURY FMJ, Bajis S, Hajarizadeh B, Marshall AD, et al
    Evaluation of the Xpert(R) HCV Viral Load Fingerstick point-of-care assay.
    J Infect Dis. 2018 Mar 9. pii: 4925218. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. PEIFFER KH, Kuhnhenn L, Jiang B, Mondorf A, et al
    Divergent preS sequences in virion associated hepatitis B virus genomes and subviral HBV surface antigen particles from HBV e antigen negative patients.
    J Infect Dis. 2018 Mar 8. pii: 4924691. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. STROUVELLE VP, Braun DL, Vongrad V, Scherrer AU, et al
    No Effect of Pegylated Interferon-alpha on Total Hiv-1 DNA Load in HIV-1/HCV Coinfected Patients.
    J Infect Dis. 2018 Mar 8. pii: 4924783. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  61. ZIMMER CL, Rinker F, Honer Zu Siederdissen C, Manns MP, et al
    Increased NK Cell Function after Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Associates with Liver Damage and HBsAg Loss.
    J Infect Dis. 2018 Feb 17. pii: 4868650. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. DOU Y, van Montfoort N, van den Bosch A, de Man RA, et al
    HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.
    J Infect Dis. 2018;217:827-839.
    PubMed     Text format     Abstract available


  63. SORIANO V, Aguilera A
    Hepatitis Delta Enters a New Therapeutic Era.
    J Infect Dis. 2018 Feb 7. pii: 4841648. doi: 10.1093.
    PubMed     Text format    


  64. YURDAYDIN C, Keskin O, Kalkan C, Karakaya F, et al
    Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease.
    J Infect Dis. 2018 Feb 7. pii: 4841647. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  65. WU JF, Song SH, Lee CS, Chen HL, et al
    Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults.
    J Infect Dis. 2018 Jan 30. pii: 4829563. doi: 10.1093.
    PubMed     Text format     Abstract available



  66. Erratum: Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2018 Jan 27. pii: 4827080. doi: 10.1093.
    PubMed     Text format    


  67. ROLT A, Le D, Hu Z, Wang AQ, et al
    Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. SANAKA S, Kasarala GR, Tillmann HL
    A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression.
    J Infect Dis. 2018 Jan 21. pii: 4770294. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. WILSON P, Parr JB, Jhaveri R, Meshnick SR, et al
    Call to action: Prevention of mother-to-child transmission of hepatitis B in Africa.
    J Infect Dis. 2018 Jan 17. pii: 4812591. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. REID M, Ma Y, Scherzer R, Price JC, et al
    Contribution of liver fibrosis and microbial translocation to immune activation in HIV and HCV.
    J Infect Dis. 2018 Jan 3. pii: 4786614. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. LIU H, Li F, Zhang X, Yu J, et al
    Differentially expressed intrahepatic genes contribute to control of hepatitis B virus replication in the inactive carrier phase.
    J Infect Dis. 2018 Jan 2. pii: 4782485. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. SU TH, Yang HC, Tseng TC, Liou JM, et al
    Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy.
    J Infect Dis. 2018 Jan 2. pii: 4782512. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  73. PERUMALSWAMI PV, Talal AH
    Improvements in Quality of Life: A New Hepatitis C Virus Treatment Indication in Persons with Substance Use Disorders.
    J Infect Dis. 2017 Dec 26. pii: 4774700. doi: 10.1093.
    PubMed     Text format    


  74. STEPANOVA M, Thompson A, Doyle J, Younossi I, et al
    Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
    J Infect Dis. 2017 Dec 26. pii: 4774699. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. BOPPANA SB, Britt WJ, Fowler K, Hutto SC, et al
    Pathogenesis of Non-Zika Congenital Viral Infections.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    November 2017
  76. BOON D, Redd AD, Layendecker O, Engle R, et al
    Hepatitis E virus seroprevalence and correlates of anti-HEV IgG antibodies in the Rakai District, Uganda.
    J Infect Dis. 2017 Nov 23. pii: 4653785. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. ROSENBERG BR, Freije CA, Imanaka N, Chen ST, et al
    Genetic variation at IFNL4 influences extrahepatic interferon stimulated gene expression in chronic HCV patients.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  78. CHAUDHURY CS, Sheehan J, Chairez C, Akoth E, et al
    No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.
    J Infect Dis. 2017 Nov 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. YANG HC, Shih YF, Liu CJ
    Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  80. SU TH, Kao JH
    Unmet Needs in Clinical and Basic Hepatitis B Virus Research.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  81. TSENG TC, Huang LR
    Immunopathogenesis of Hepatitis B Virus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  82. WU D, Ning Q
    Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  83. LIU CJ, Kao JH
    NOhep: Toward Global Control of Hepatitis B Virus Infection-An Introduction.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  84. CHOI J, Lim YS
    Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  85. BUTI M, Riveiro-Barciela M, Esteban R
    Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  86. CHEN HL, Wen WH, Chang MH
    Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  87. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  88. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. CHANG Y, Choe WH, Sinn DH, Lee JH, et al
    Nucleos(t)ide Analogue Treatment for Adult Patients with HBeAg-positive Chronic Infection with Genotype C Hepatitis B Virus: A Nationwide Real-life Study.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


    August 2017
  91. BOEIJEN LL, Montanari NR, de Groen RA, van Oord GW, et al
    Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  92. HEIMER R, Binka M, Koester S, Grund JC, et al
    Recovery of Infectious Hepatitis C Virus from Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.
    J Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


    April 2017
  94. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  95. VAN DER REE MH, Jansen L, Kruize Z, van Nuenen AC, et al
    Plasma microRNA levels are associated with HBeAg status and treatment response in chronic hepatitis B patients.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. CHI H, Hansen BE, Guo S, Zhang NP, et al
    Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    J Infect Dis. 2017 Mar 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. CHEN GJ, Lin KY, Hung CC, Chang SC, et al
    Hepatitis A outbreak among men who have sex with men in a country of low endemicity of hepatitis A infection.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  98. WANG L, Wen J, Gao F, Hao H, et al
    Hepatitis E virus-associated neurological injury in China.
    J Infect Dis. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format    


  99. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  100. HAN Y, Gu L, Liu J, Li X, et al
    Association of mutations in TLR2 signaling genes with fulminant form of hepatitis B related acute liver failure.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  101. CAO J, Chi H, Yu T, Li Z, et al
    Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    J Infect Dis. 2017 Jan 19. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2016
  102. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  103. UCHIYAMA S, Keller N, Schlaepfer E, Grube C, et al
    Interferon alpha-Enhanced Clearance of Group A Streptococcus Despite Neutropenia.
    J Infect Dis. 2016;214:321-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: